Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to evaluate safety and pharmacokinetics of single ascending IV doses of GMI-1359 in healthy adult subjects.
Condition or disease
Drug: GMI-1359Drug: Placebo
This is a randomized, double-blind, placebo-controlled, single ascending IV dose study conducted at one study center in the United States. Safety will be assessed throughout the study and serial blood samples and urine samples will be collected for the safety and pharmacokinetic assessment of GMI-1359.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
19 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy adult male or females, 19-60 years of age (inclusive).
Medically healthy with no clinically significant screening results.
Females of childbearing potential must either be sexually inactive (abstinent) for 3 months prior to dosing or be using an acceptable birth control method
Females must have a negative pregnancy test at the time of screening and prior to dosing for inclusion in the study.
Understands the study procedures in the informed consent form, and be willing and able to comply with the protocol.
Subject is mentally or legally incapacitated.
History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subjects by their participation in the study.
Normal clinical laboratory values.
Normal heart rate and blood pressure.
Blood donation or significant blood loss within 56 days prior to dosing.
Plasma donation within 7 days prior to dosing.
Participation in another clinical trial within 28 days prior to dosing.